Oramed Pharmaceuticals Inc   (ORMP)
Other Ticker:  
Price: $2.2000 $0.03 1.382%
Day's High: $2.2601 Week Perf: 1.85 %
Day's Low: $ 2.14 30 Day Perf: 19.57 %
Volume (M): 163 52 Wk High: $ 13.73
Volume (M$): $ 359 52 Wk Avg: $3.55
Open: $2.17 52 Wk Low: $1.67

 Market Capitalization (Millions $) 89
 Shares Outstanding (Millions) 40
 Employees 21
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 15
 Cash Flow (TTM) (Millions $) -32
 Capital Exp. (TTM) (Millions $) 0

Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development of oral drug delivery systems for the treatment of diabetes and other diseases. The company has developed a proprietary oral insulin capsule as well as an oral GLP-1 analog capsule for the treatment of Type 1 and Type 2 diabetes.

Oramed's technology is based on a platform of orally ingestible capsules containing peptides, proteins, and other molecules that are delivered directly to the small intestine. This approach has been designed to overcome the limitations of traditional insulin injection therapy, which often results in poor patient adherence due to the need for frequent injections and the pain and inconvenience associated with them.

In addition to its diabetes therapies, Oramed is also developing an oral leptin capsule for the treatment of obesity and related metabolic disorders. Leptin is a hormone that plays a key role in regulating energy balance and appetite, and Oramed's oral formulation has the potential to overcome the limitations of injectable leptin therapies.

Oramed was founded in 2006 by Dr. Miriam Kidron, a pharmacist and biochemist, and Nadav Kidron, a lawyer and business executive. The company is headquartered in New York, with research and development facilities located in Jerusalem, Israel.

Since its inception, Oramed has been dedicated to the development of innovative drug delivery technologies that have the potential to transform the treatment of diabetes and other diseases. The company has a strong patent portfolio and an experienced management team with a track record of success in bringing new therapies to market.

Oramed's clinical pipeline includes multiple Phase II and Phase III clinical trials for its diabetes and obesity therapies. The company has received funding and support from prominent investors and organizations, including the Israeli Innovation Authority, the National Institutes of Health, and various venture capital firms.

Overall, Oramed Pharmaceuticals Inc. is a promising biotech company with a strong focus on developing innovative oral drug delivery systems for the treatment of diabetes, obesity, and related metabolic disorders. With a solid pipeline of clinical-stage candidates and a team of experienced researchers and executives, the company has the potential to deliver significant value to patients and investors alike.

   Company Address: 1185 Avenue of the Americas New York 10036 NY
   Company Phone Number: 967-2633   Stock Exchange / Ticker: NASDAQ ORMP
   ORMP is expected to report next financial results on March 05, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc Overcomes Revenue Setback, Prepares for Resurgence in Q4 2023

Enanta Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections, recently announced its financial results for the July to September 30, 2023, period. During this period, the company reported an increase in losses, which expanded from $1.27 per share a year prior to $1.32 per share. However, it is worth noting that the earnings per share (EPS) improved from -$1.86 in the preceding reporting period.
The revenue for the same period decreased by 6.817% to $18.93 million compared to $20.32 million in the previous reporting period. While sequentially, the revenue advanced slightly by 0.212% from $18.89 million. This decline in revenue could raise concerns, as it may indicate slowing demand for Enanta Pharmaceuticals Inc's products.

Procyon Corporation

Procyon Corporation Steams Ahead, Consolidating Revenue at PCYN in Record-breaking Quarter

Based on the financial time-frame ending September 30, 2023, Procyon Corporation has experienced significant declines and challenges, leading to a bearish outlook for the company. Depleting orders have played a crucial role in the losses incurred during this period.
The revenue for Procyon Corporation fell by -0.221% to $1.17 million compared to the previous reporting season, where revenue decreased by -2.42% from $1.20 million. This downward trend indicates a constant struggle for the company to maintain a steady revenue stream. It is clear that Procyon Corporation has been facing difficulties in generating consistent income.

China Health Industries Holdings Inc

Impressive 11.069% Revenue Surge Demonstrates China Health Industries Holdings Inc's Strong Growth Potential in Q3 2023

China Health Industries Holdings Inc (CHHE) recently announced its financial results for the fiscal period ending September 30, 2023. These results demonstrate the company's ability to achieve top-line growth despite industry-wide revenue reductions. Additionally, CHHE's inventories have declined, indicating potential future demand. This article will outline the facts and set the current financial results into context.
Financial Results Overview:
For the fiscal period ending September 30, 2023, CHHE reported a zero gain of $0.00 per share, compared to a loss of $0.01 per share during the same period a year ago. Sequentially, CHHE improved from a loss of $0.01 per share in the previous quarter. This indicates progress in generating profits and more favorable financial performance.

Acer Therapeutics Inc

Acer Therapeutics Inc Reports Revenue of $0.37179 Million in Q3 2023 Financial Report amidst Concerns of Declining Stock Performance

The stock performance of a company plays a vital role in determining its overall financial health. Acer Therapeutics Inc, a major player in the pharmaceutical preparations industry, has experienced a decline in its stock price over the past week, negatively impacting its year-to-date performance. This article aims to provide an overview of the recent trends seen in Acer Therapeutics Inc's stock performance, along with insights into the company's financial records and future expectations.
Stock Performance
Over the past week, Acer Therapeutics Inc's stock has experienced a decline, although the exact percentage decrease is undisclosed in the provided information. This downtrend has brought the company's year-to-date performance to a staggering -74.81%. Consequently, investors may have concerns about the company's financial stability, prompting a closer examination of its financial records.

Baudax Bio Inc

Baudax Bio Inc's Revenue Shows Steady Comparison to Previous Year During July-September 2023 Period

Baudax Bio Inc, a pharmaceutical company listed on the NASDAQ, recently released its financial results for the July to September 2023 period. The company demonstrated significant improvements in its loss per share and earnings per share compared to the previous year and the previous quarter. Despite revenue remaining unchanged, Baudax Bio Inc reported a substantial decrease in its net shortfall. This article aims to outline the facts and interpret these financial results.
1. Improving Financial Performance:
For the July to September 2023 period, Baudax Bio Inc managed to decrease its loss per share from $-2.47 to $-0.30 when compared to the same quarter last year, showcasing a remarkable improvement. Moreover, earnings per share saw significant growth from $-1.51 in the previous quarter to the current quarter.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com